Related Experiment Videos

Association between LDL-cholesterol, statin therapy, physical activity and inflammatory markers in patients with

D König1, P Deibert, K Winkler

  • 1Centre for Internal Medicine, Department of Rehabilitation, Prevention and Sports Medicine, Freiburg University Hospital, Germany. Koenig@msm1.ukl.uni-freiburg.de

Exercise Immunology Review
|January 3, 2006
PubMed

Insights

Lipid lowering drugs and high physical activity are associated with reduced inflammatory markers in coronary heart disease patients. Combining both interventions showed the most significant reduction in C-reactive protein and serum amyloid-A.

Area of Science:

  • Cardiology
  • Biochemistry
  • Preventive Medicine

Background:

  • Inflammatory markers like hs-CRP, IL-6, SAA, and fibrinogen are linked to cardiovascular disease.
  • Understanding factors influencing these markers is crucial for managing coronary heart disease (CHD).

Purpose of the Study:

  • To investigate the association between LDL-cholesterol (LDL-C), lipid-lowering drug therapy (LLD), and inflammatory markers in CHD patients.
  • To examine the effects of physical activity (PA) alone and in combination with LLD on inflammatory markers.

Main Methods:

  • Cross-sectional study of 436 CHD patients in cardiac rehabilitation.
  • Subgroup analysis (n=229) assessed effects of PA and LLD.
  • Measured inflammatory markers: hs-CRP, IL-6, SAA, fibrinogen.
  • Categorized patients based on LLD use, LDL-C levels, and PA frequency.

Main Results:

  • LLD therapy was associated with modestly lower hs-CRP and IL-6 levels.
  • Lower LDL-C (< 100 mg/dl) correlated with significantly lower hs-CRP and fibrinogen.
  • High PA (≥ 3 times/week) was linked to significantly lower hs-CRP, fibrinogen, and SAA.
  • Combination of high PA and LLD showed the most pronounced reduction in hs-CRP and SAA.

Conclusions:

  • LLD, optimal LDL-C control, and high physical activity are associated with reduced inflammatory markers in CHD patients.
  • High PA combined with LLD demonstrates the strongest effect on lowering specific inflammatory markers.
  • Further randomized controlled trials are needed to establish causality.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Inflammation01:38

Inflammation

Overview
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...